Accutar Biotechnology

Brooklyn, United States Founded: 2015 • Age: 11 yrs
AI-assisted tools for drug discovery are developed.
Request Access

About Accutar Biotechnology

Accutar Biotechnology is a company based in Brooklyn (United States) founded in 2015 by Jie Fan.. Accutar Biotechnology has raised $91.45 million across 5 funding rounds from investors including Primavera Capital Group, YITU and Yunfeng Capital. Accutar Biotechnology offers products and services including ChemiRise, Orbital, Virtual Screen, Intelligent-SAR, and Chemi-Net. Accutar Biotechnology operates in a competitive market with competitors including Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others.

  • Headquarter Brooklyn, United States
  • Founders Jie Fan
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Accutar Biotechnology Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $91.45 M (USD)

    in 5 rounds

  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Accutar Biotechnology

Accutar Biotechnology offers a comprehensive portfolio of products and services, including ChemiRise, Orbital, Virtual Screen, Intelligent-SAR, and Chemi-Net. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

AI tool for accelerating chemical compound discovery.

Virtual screening platform for drug candidate identification.

System for intelligent drug design and analysis.

Tool for structure-activity relationship predictions.

Network for chemical data modeling and predictions.

People of Accutar Biotechnology
Headcount 10-50
Employee Profiles 18
Board Members and Advisors 4
Employee Profiles
People
Aaron Feng Chen
Chief Business Officer
People
Xiangyan Sun
Chief Technology Officer
People
Jie Fan
Founder & CEO
People
Wei He
Chief Scientific Officer

Unlock access to complete

Board Members and Advisors
people
Carlos Garcia-Echeverria
Advisor
people
Qi Liu
Advisor
people
Pasi A. Jänne
Advisor

Unlock access to complete

Funding Insights of Accutar Biotechnology

Accutar Biotechnology has successfully raised a total of $91.45M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round
  • First Round

    (06 Dec 2017)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2021 Amount Series C - Accutar Biotechnology Valuation Yunfeng Capital , Coatue
Jan, 2021 Amount Series C - Accutar Biotechnology Valuation

investors

Sep, 2020 Amount Series B - Accutar Biotechnology Valuation Primavera , CDH
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Accutar Biotechnology

Accutar Biotechnology has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Primavera Capital Group, YITU and Yunfeng Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity investments are managed by Yunfeng Capital in China.
Founded Year Domain Location
Provider of an investment platform for various stages
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Accutar Biotechnology

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Accutar Biotechnology

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Accutar Biotechnology Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Accutar Biotechnology

Accutar Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
AI-powered drug discovery platform for various diseases
domain founded_year HQ Location
An agentic AI platform is developed for biomedical research insights.
domain founded_year HQ Location
Antibody therapies are developed through machine learning and synthetic biology.
domain founded_year HQ Location
AI platform used for extracting antibody data from scientific papers.
domain founded_year HQ Location
AI-based platform for cancer diagnostics and precision medicine is utilized.
domain founded_year HQ Location
AI-driven drug discovery platform for the treatment of cancer
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Accutar Biotechnology

Frequently Asked Questions about Accutar Biotechnology

When was Accutar Biotechnology founded?

Accutar Biotechnology was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Accutar Biotechnology located?

Accutar Biotechnology is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.

Who is the current CEO of Accutar Biotechnology?

Jie Fan is the current CEO of Accutar Biotechnology. They have also founded this company.

Is Accutar Biotechnology a funded company?

Accutar Biotechnology is a funded company, having raised a total of $91.45M across 5 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Dec 06, 2017.

What does Accutar Biotechnology do?

Accutar Biotechnology was founded in 2015 and is based in Brooklyn, United States. Operations focus on computation-aided drug discovery within the biotechnology sector. An AI-assisted tool has been developed for predicting drug pocket side-chain conformations and performing drug docking, with accuracy exceeding standard methods. Chemical compound properties, such as solubility and binding affinity, are also predicted. Platforms include Orbital Docking and One-click Docking for these functions.

Who are the top competitors of Accutar Biotechnology?

Accutar Biotechnology's top competitors include Owkin, Formation Bio and XtalPi.

What products or services does Accutar Biotechnology offer?

Accutar Biotechnology offers ChemiRise, Orbital, Virtual Screen, Intelligent-SAR, and Chemi-Net.

Who are Accutar Biotechnology's investors?

Accutar Biotechnology has 8 investors. Key investors include Primavera Capital Group, YITU, Yunfeng Capital, Coatue, and 3W Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available